제품 수집
제품 세부정보
Synonyms
EGFRvIII
Source
Alexa Fluor 488-Labeled Human EGFRvIII, His Tag (EGI-HA2H7) is produced via conjugation of AF488 to Human EGFRvIII, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human EGFRvIII, His Tag is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Predicted N-terminus: Leu 25
Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
Conjugate
AF488
Excitation Wavelength: 488 nm
Emission Wavelength: 517 nm
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Evaluation of CAR expression
FACS Analysis of Anti-EGFRvIII CAR Expression
5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 20 μg/mL of Alexa Fluor 488-Labeled Human EGFRvIII, His Tag (Cat. No. EGI-HA2H7) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa Fluor 488 signal was used to evaluate the binding activity (QC tested).
ProtocolFACS Analysis of Non-specific binding to PBMCs
5e5 of PBMCs were stained with Alexa Fluor 488-Labeled Human EGFRvIII, His Tag (Cat. No. EGI-HA2H7) and anti-CD3 antibody, washed and then analyzed with FACS. PE signal was used to evaluate the expression of CD3+ T cells in PBMCs, and Alexa Fluor 488 signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Protocol
사용자 리뷰 댓글 남기기
배경 소개
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.
프론티어 진행
의약품 개발 진행- 영어 이름：
Epidermal growth factor receptor variant III
- 카테고리：
- 상장 의약품 수：
0 상세
- 임상 의약품 수：
14 상세
- 최고 개발 단계：
Phase 2 Clinical
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
